Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- DRUG: Ibrutinib
- DRUG: Next-line ibrutinib
Sponsor
Pharmacyclics LLC.
Collaborators